Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 29fludarabine phosphate 22Whole-Body Irradiation 20Mycophenolic Acid 20fludarabine 19asciminib 19nilotinib 16Tacrolimus 13Imatinib Mesylate 13Melphalan 11Dasatinib 9Sirolimus 8Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Granulocyte Colony-Stimulating Factor 7Busulfan 7bosutinib 6Mesna 6Cyclosporine 6ponatinib 5Stem Cell Transplantation 5Filgrastim 5venetoclax 4ruxolitinib 4blinatumomab 4Specimen Handling 4Cyclosporins 4thymoglobulin 3Bone Marrow Transplantation 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Calcineurin Inhibitors × 1 year × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡